GLP-1 receptor agonists, originally developed to treat type 2 diabetes and obesity, are being investigated as potential treatments for addictions to alcohol, nicotine, opioids and other substances. Preclinical studies show that these drugs can reduce cravings, suppress drug seeking, and reduce relapses. The mechanism lies in the modulation of the brain's reward circuits, particularly in interaction with the dopamine system and areas such as the ventral tegmental area and nucleus accumbens, which regulate motivation and reward. Clinical trials are small so far, and the results are promising, for example, one study showed a reduction in heavy drinking in patients with alcohol dependence, and another showed a 40% reduction in opioid cravings over three weeks. Research also suggests that GLP-1 agonists may reduce the activity of brain regions associated with reward and addiction. The development of new drugs targeting specifically the brain with better permeability through the blood-brain barrier is in process. However, further large and long-term studies are needed to confirm the effectiveness and safety of these drugs in the treatment of addictions[1][2][3][4][5][6].